Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Treatment of Malaria-Associated Acute Kidney Injury and Progression to Chronic Kidney Disease

Award Number: R16GM159172
ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2025
PERIOD OF PERFORMANCE END DATE: 05/31/2029

Group Awards By:

View Award Description

Treatment of Malaria-Associated Acute Kidney Injury and Progression to Chronic Kidney Disease - PROJECT SUMMARY Malaria continues to be one of the top five leading causes of death in children under five, claiming the lives of roughly half a million children annually. In most cases, the infection manifests as the so-called uncomplicated or mild malaria, which resembles flu-like symptoms. However, if left untreated, malaria can rapidly progress to severe malaria, a potentially life-threatening complication with mortality rates up to 90% at home and 20% when patients are treated in hospital. Among the different manifestations of patients with severe malaria, ma- laria-associated acute kidney injury (MAKI) has emerged as one of the most common maladies; it is associated with poor prognosis and one of the strongest predictors of death. The impact of MAKI is beyond the associated mortality. After an episode of acute kidney injury, the risk of developing long-term neurological complications and chronic kidney disease (CKD) increases, even if the patient experiences a complete short-term recovery and has no pre-existing medical conditions. In addition, people growing up in hyperendemic areas of malaria are exposed to multiple episodes of malaria during their lifetime, with an estimated mean of 47.5 malaria infections since birth, thus multiplying the chances of developing both MAKI and CKD. The management recommendations of MAKI involve renal replacement therapy (RRT) in 25-75% of patients. The most commonly used interventions for RRT include hemodialysis, peritoneal dialysis, hemofiltration, and kidney transplantation. However, implementing these treatments in low-and middle-income countries, where malaria is endemic, poses multiple challenges, includ- ing financial constraints, limited infrastructure, and scarcity of trained personnel. Therefore, alternative therapies designed specifically for resource-limited regions are urgently needed to improve outcomes and reduce the burden of MAKI and the development of CKD. The central hypothesis is that ferroptosis and the FasL/Fas extrinsic apoptosis cell death pathways are pivotal in the pathogenesis of MAKI and that recurrent malaria in- fections elevate the risk of MAKI development and progression to CKD. This research proposal aims to extend our investigation into malaria-associated kidney disease, focusing on the therapeutic potential of targeting these two cell death pathways for treating MAKI. Additionally, utilizing our innovative mouse model of MAKI and in vitro systems, we will elucidate the mechanisms underlying the progression of MAKI to CKD and exam- ine the impact of multiple malaria infections on disease outcomes. The long-term goal of these studies is to develop alternatives to RRT to treat MAKI that can be implemented in low-and middle-income countries where this therapy is largely unavailable and to understand how multiple malar- ia infections contribute to the development of MAKI and the progression to CKD. To this end, we will (1) Targeting the ferroptosis cell death pathway as a potential therapeutical target in MAKI. (2) Determine the role of the extrinsic apoptosis pathway Fas/Caspase-8 in MAKI and its potential as a therapeutical target. (3) Investigating MAKI à CKD progression following multiple malaria infections in our mouse model.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $132,245 )
2026	2026	RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK	250 BEDFORD PARK BLVD W	BRONX	NY	10468	BRONX	USA	Biomedical Research and Research Training	000	2	4/29/2026	NON-COMPETING CONTINUATION	$132,245
														Subtotal = $132,245

Issue Date FY: 2025 ( Subtotal = $131,613 )
2025	2025	RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK	250 BEDFORD PARK BLVD W	BRONX	NY	10468	BRONX	USA	Biomedical Research and Research Training	000	1	8/28/2025	NEW	$131,613
														Subtotal = $131,613

Grand Total All Awards = $263,858

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Treatment of Malaria-Associated Acute Kidney Injury and Progression to Chronic Kidney Disease

Award Number: R16GM159172

ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2025

PERIOD OF PERFORMANCE END DATE: 05/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer